Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07BCO
|
|||
| Former ID |
DNC001509
|
|||
| Drug Name |
WAY-100635
|
|||
| Synonyms |
N-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; 162760-96-5; Way 100635; UNII-71IH826FEG; CHEMBL31354; 71IH826FEG; N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; WAY100635; Rec 0/0277; [3H]WAY100635; WAY 100,635; WAY-100,635; Lopac-W-108; AC1L1KWK; GTPL80; AC1Q5IB0; SCHEMBL84178; Lopac0_001229; WAY-100635 maleate salt/; GTPL3251; BDBM86708; DTXSID20167467; CHEBI:125619; EX-A1053; ZINC52541473; 2799AH; PDSP2_001699; PDSP1_001716; ABP000343; AKOS027313833; SB19513; NSC_104911; CS-0418; CCG-205303
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Eating disorder [ICD-11: 6B82; ICD-10: F50, F98.2] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H34N4O2
|
|||
| Canonical SMILES |
COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4
|
|||
| InChI |
1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
|
|||
| InChIKey |
SBPRIAGPYFYCRT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 162760-96-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5450228, 7980890, 8153485, 11111964, 14856089, 29224721, 47736663, 47885576, 48110625, 49957645, 50111272, 53789487, 77798686, 85208883, 90340807, 103202618, 103817218, 103856046, 103943539, 104309953, 117568341, 124750337, 124881811, 129212842, 135651215, 135651321, 136349538, 136352757, 136367669, 142456119, 152258190, 152344121, 160647026, 162038085, 162108920, 162202772, 164766157, 172919870, 185998777, 198938426, 226462650, 252473864
|
|||
| ChEBI ID |
CHEBI:125619
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Antagonist | [3], [4], [5], [6] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 80). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002783) | |||
| REF 3 | Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635. Life Sci. 1997;60(9):653-65. | |||
| REF 4 | 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002 Jun;301(3):1144-50. | |||
| REF 5 | Cocaine and serotonin: a role for the 5-HT(1A) receptor site in the mediation of cocaine stimulant effects. Behav Brain Res. 2001 Nov 29;126(1-2):127-33. | |||
| REF 6 | Involvement of 5-hydroxytryptamine(1A) receptors in nicotine-induced tail tremor in rats. Eur J Pharmacol. 2000 Nov 10;408(1):19-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.